TuHURA Biosciences (NASDAQ:HURA) Stock Rating Reaffirmed as “Buy” by HC Wainwright

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright‘s price target suggests a potential upside of 373.93% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Up 3.4%

HURA traded up $0.07 on Tuesday, reaching $2.11. 398,392 shares of the company traded hands, compared to its average volume of 876,437. The stock’s 50 day moving average price is $2.04 and its 200-day moving average price is $1.93. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43. The company has a market cap of $134.47 million, a price-to-earnings ratio of -3.91 and a beta of -0.21. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, sell-side analysts expect that TuHURA Biosciences will post -0.55 EPS for the current fiscal year.

Institutional Trading of TuHURA Biosciences

Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new stake in TuHURA Biosciences in the second quarter worth approximately $81,000. HighTower Advisors LLC boosted its holdings in shares of TuHURA Biosciences by 42.5% during the 2nd quarter. HighTower Advisors LLC now owns 30,151 shares of the company’s stock worth $71,000 after buying an additional 8,999 shares during the period. Two Sigma Securities LLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $33,000. Hsbc Holdings PLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $69,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $98,000. 0.62% of the stock is owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.